《Diabetes Obesity & Metabolism》雜志的最新年發(fā)文量為383篇。
這表明該刊在每年都會精選并發(fā)表一定數(shù)量的高質(zhì)量文章，以保持其在內(nèi)分泌學(xué)與代謝領(lǐng)域的學(xué)術(shù)影響力。
該刊聚焦于醫(yī)學(xué)-內(nèi)分泌學(xué)與代謝領(lǐng)域的前沿研究，致力于推動該領(lǐng)域新技術(shù)和新知識的傳播與應(yīng)用。同時它積極鼓勵研究人員詳細發(fā)表其高質(zhì)量的實驗研究和理論成果。
該刊的平均審稿周期約為 一般,3-8周 。
Diabetes Obesity & Metabolism 雜志發(fā)文統(tǒng)計
文章名稱引用次數(shù)
- Incretin hormones: Their role in health and disease70
- Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis65
- Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease42
- Identification of barriers to insulin therapy and approaches to overcoming them38
- GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials35
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis35
- Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials35
- Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review35
- Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial33
- Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study33
國家/地區(qū)發(fā)文量
- USA487
- England302
- GERMANY (FED REP GER)159
- Denmark147
- Canada137
- Italy137
- CHINA MAINLAND109
- Netherlands90
- Sweden90
- Australia88
